Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Magnetophoretic Intranasal Drug-loaded Magnetic Nano-aggregates as a Platform for Drug Delivery in Status Epilepticus

Author(s): Ali Hemmat, Erfaneh Ghassami*, Mohsen Minaiyan and Jaleh Varshosaz

Volume 11, Issue 2, 2023

Published on: 16 February, 2023

Page: [155 - 166] Pages: 12

DOI: 10.2174/2211738511666230106154557

Price: $65

Abstract

Background: Status epilepticus is associated with substantial morbidity and neuronal necrosis, and the duration of the seizure would affect its following complications. Eliminating the duration would have valuable outcomes; however, the presence of BBB is an obstacle. The purpose of the current study was to achieve a nose-to-brain magnetic drug delivery system to accelerate the onset of action, and to reduce the mucociliary clearance via implementing the magnetic field.

Materials and Methods: The drug-entrapped magnetic nanoaggregates were prepared via a 2-step method, synthesis of the magnetic nanoparticles and drug loading. Optimization of the variables, including ammonium hydroxide:water ratio, beta-cyclodextrin%, duration of the mixing time, amount of Pluronic, and drug:magnetic nanoaggregates mass ratio was performed according to particle size, PDI, zeta potential, release profile and entrapment efficiency. The efficacy of optimized formulation was assessed in the animal model.

Results: According to the analysis performed by the software, drug-to-nanoparticle ratio and the duration of mixing time were found to be significantly effective (p < 0.05) for entrapment efficiency and particle size distribution, respectively. The optimum formulation with an approximate average size of 581 nm and 61% entrapment efficiency was obtained, which released about 80% of its drug content within the first 20 minutes. The in vivo efficacy was significantly improved (p < 0.05) by administration of magnetic nanoaggregates in the presence of a simple external magnet placed on the glabellar region of the animals, compared to the control groups.

Conclusion: This drug delivery system could be suggested as a fast-acting alternative for seizure cessation in status epilepticus emergencies.

« Previous Next »
Graphical Abstract

[1]
Fact sheet: epilepsy. World Health Organization 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/epilepsy
[2]
Newton CR, Garcia HH. Epilepsy in poor regions of the world. Lancet 2012; 380(9848): 1193-201.
[http://dx.doi.org/10.1016/S0140-6736(12)61381-6] [PMID: 23021288]
[3]
Fisher RS, Bonner AM. The revised definition and classification of epilepsy for neurodiagnostic technologists. Neurodiagn J 2018; 58(1): 1-10.
[http://dx.doi.org/10.1080/21646821.2018.1428455] [PMID: 29562876]
[4]
Fisher RS. The new classification of seizures by the international league against epilepsy 2017. Curr Neurol Neurosci Rep 2017; 17(6): 48.
[http://dx.doi.org/10.1007/s11910-017-0758-6] [PMID: 28425015]
[5]
Thijs RD, Surges R, O’Brien TJ, Sander JW. Epilepsy in adults. Lancet 2019; 393(10172): 689-701.
[http://dx.doi.org/10.1016/S0140-6736(18)32596-0] [PMID: 30686584]
[6]
Thomas SV, Cherian A. Status epilepticus. Ann Indian Acad Neurol 2009; 12(3): 140-53.
[http://dx.doi.org/10.4103/0972-2327.56312] [PMID: 20174493]
[7]
Trinka E, Kälviäinen R. 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure 2017; 44: 65-73.
[http://dx.doi.org/10.1016/j.seizure.2016.11.001] [PMID: 27890484]
[8]
Liu Q, Zhang Q. Nanoparticle systems for nose-to-brain delivery. In: Brain Targeted Drug Delivery System. Elsevier Amsterdam 2019; pp. 219-39.
[http://dx.doi.org/10.1016/B978-0-12-814001-7.00010-X]
[9]
Munaz A, Shiddiky MJA, Nguyen NT. Recent advances and current challenges in magnetophoresis based micro magnetofluidics. Biomicrofluidics 2018; 12(3)031501
[http://dx.doi.org/10.1063/1.5035388] [PMID: 29983837]
[10]
Brodie MJ, Kwan P. Current position of phenobarbital in epilepsy and its future. Epilepsia 2012; 53 (Suppl. 8): 40-6.
[http://dx.doi.org/10.1111/epi.12027] [PMID: 23205961]
[11]
Jilek-Aall L, Rwiza HT. Prognosis of epilepsy in a rural African community: A 30-year follow-up of 164 patients in an outpatient clinic in rural Tanzania. Epilepsia 1992; 33(4): 645-50.
[http://dx.doi.org/10.1111/j.1528-1157.1992.tb02341.x] [PMID: 1628578]
[12]
Li J, Yang D, Zhao D, Li N, Lin W. Efficacy of phenobarbital and sodium valproate in treating convulsive epilepsy in rural northeast China. Seizure 2019; 71: 207-13.
[http://dx.doi.org/10.1016/j.seizure.2019.06.012] [PMID: 31394367]
[13]
Mani KS, Rangan G, Srinivas HV, Sridharan VS, Subbakrishna DK. Epilepsy control with phenobarbital or phenytoin in rural south India: The Yelandur study. Lancet 2001; 357(9265): 1316-20.
[http://dx.doi.org/10.1016/S0140-6736(00)04516-5] [PMID: 11343735]
[14]
Nimaga K, Desplats D, Doumbo O, Farnarier G. Treatment with phenobarbital and monitoring of epileptic patients in rural Mali. Bull World Health Organ 2002; 80(7): 532-7.
[PMID: 12163916]
[15]
Sykes RM. Epilepsy in children in benin city, Nigeria. Ann Trop Paediatr 2002; 22(3): 287-96.
[http://dx.doi.org/10.1179/027249302125001598] [PMID: 12369496]
[16]
Ragab DM, Rohani S, Consta S. Controlled release of 5-fluorouracil and progesterone from magnetic nanoaggregates. Int J Nanomedicine 2012; 7: 3167-89.
[PMID: 22802683]
[17]
Xia H, Foo P, Yi J. Water-dispersible spherically hollow clusters of magnetic nanoparticles. Chem Mater 2009; 21(12): 2442-51.
[http://dx.doi.org/10.1021/cm900268z]
[18]
Wasterlain CG, Fujikawa DG, Penix L, Sankar R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993; 34(s1): S37-53.
[http://dx.doi.org/10.1111/j.1528-1157.1993.tb05905.x] [PMID: 8385002]
[19]
Bone RC. Status epilepticus. JAMA 1993; 270(7): 854-9.
[PMID: 8340986]
[20]
Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: Prospective randomised study. BMJ 2000; 321(7253): 83-6.
[http://dx.doi.org/10.1136/bmj.321.7253.83] [PMID: 10884257]
[21]
Nair SC, Vinayan KP, Mangalathillam S. Nose to brain delivery of phenytoin sodium loaded nano lipid carriers: Formulation, drug release, permeation and in vivo pharmacokinetic studies. Pharmaceutics 2021; 13(10): 1640.
[http://dx.doi.org/10.3390/pharmaceutics13101640] [PMID: 34683933]
[22]
Yousfan A, Rubio N, Al-Ali M, Nattouf AH, Kafa H. Intranasal delivery of phenytoin-loaded nanoparticles to the brain suppresses pentylenetetrazol-induced generalized tonic clonic seizures in an epilepsy mouse model. Biomater Sci 2021; 9(22): 7547-64.
[http://dx.doi.org/10.1039/D1BM01251G] [PMID: 34652351]
[23]
Dehvari K, Lin KS, Wang SSS. Structural characterization and adsorption properties of pluronic F127 onto iron oxides magnetic nanoparticles. J Nanosci Nanotechnol 2014; 14(3): 2361-7.
[http://dx.doi.org/10.1166/jnn.2014.8537] [PMID: 24745232]
[24]
Merkus F, Verhoef JC, Marttin E, Romeijn SG, Hermens WA, Schipper NG. Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 1999; 36(1): 41-57.
[http://dx.doi.org/10.1016/S0169-409X(98)00054-4] [PMID: 10837708]
[25]
Sharma D, Sharma RK, Sharma N, et al. Nose-to-brain delivery of PLGA-diazepam nanoparticles. AAPS PharmSciTech 2015; 16(5): 1108-21.
[http://dx.doi.org/10.1208/s12249-015-0294-0] [PMID: 25698083]
[26]
Bakandritsos A, Mattheolabakis G, Zboril R, et al. Preparation, stability and cytocompatibility of magnetic/PLA-PEG hybrids. Nanoscale 2010; 2(4): 564-72.
[http://dx.doi.org/10.1039/b9nr00253g] [PMID: 20644760]
[27]
Chen P, Song H, Yao S, Tu X, Su M, Zhou L. Magnetic targeted nanoparticles based on β-cyclodextrin and chitosan for hydrophobic drug delivery and a study of their mechanism. RSC Advances 2017; 7(46): 29025-34.
[http://dx.doi.org/10.1039/C7RA02398G]
[28]
Huang L, Wang H, Li B, et al. β-Cyclodextrin derivatives hybrid Fe3O4 magnetic nanoparticles as the drug delivery for ketoprofen. J Incl Phenom Macrocycl Chem 2014; 80(3-4): 209-15.
[http://dx.doi.org/10.1007/s10847-013-0378-y]
[29]
Kouli M, Kourinou M, Kokkinopoulos I, et al. A simple and rapid preparation of Fe3O4/β-cyclodextrin magnetic nanoparticles via microwave assisted co-precipitation compared with improved coprecipitation method.
[30]
Ramasamy S, Sam David RJR, Enoch IV. Folate-molecular encapsulator-tethered biocompatible polymer grafted with magnetic nanoparticles for augmented drug delivery. Artificial cells, nanomedicine, and biotechnology 2018; 46(S2): 675-82.
[http://dx.doi.org/10.1080/21691401.2018.1468340]
[31]
Salazar S, Yutronic N, Jara P. Magnetic β-cyclodextrin nanosponges for potential application in the removal of the neonicotinoid dinotefuran from wastewater. Int J Mol Sci 2020; 21(11): 4079.
[http://dx.doi.org/10.3390/ijms21114079] [PMID: 32517363]
[32]
Potschka H, Fedrowitz M, Löscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood–brain barrier: Evidence from microdialysis experiments in rats. Neurosci Lett 2002; 327(3): 173-6.
[http://dx.doi.org/10.1016/S0304-3940(02)00423-8] [PMID: 12113905]
[33]
Czapp M, Bankstahl JP, Zibell G, Potschka H. Brain penetration and anticonvulsant efficacy of intranasal phenobarbital in rats. Epilepsia 2008; 49(7): 1142-50.
[http://dx.doi.org/10.1111/j.1528-1167.2008.01582.x] [PMID: 18363707]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy